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Bovine mastitis is a costly disease in the U.S. dairy industry.  Its major causative 
agent Staphylococcus aureus is often unresponsive to antibiotic therapy.  Our first 
study examined terpeneless, cold-pressed Valencia (CPV) orange oil as a possible 
alternative to antibiotic therapy in the treatment of S. aureus associated bovine 
mastitis.  Orange oil showed significant inhibition of S. aureus growth and invasion 
of bovine epithelial mammary cells, but only modest reductions in pre-formed 
biofilms, which contribute to persistence of S. aureus infections.  Our second study 
examined major components of terpeneless, CPV orange oil.  Of four major 
compounds tested, only citral and linalool had significant inhibitory effects on S. 
aureus growth.  In addition, they were capable of reducing pre-formed biofilms as 
well as association and invasion to bovine epithelial mammary cells.  Part of this 
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Chapter 1: Introduction 
Bovine Mastitis 
Infection in Dairy Cattle  
Bovine mastitis is described as inflammation of the udder tissue.  It can affect 
one or more quarters of the udder.  Clinical symptoms may only include changes in 
the milk such as watery appearance, pus, flakes, clots, and blood.  Symptoms of 
increased severity often include changes in the milk and hardness, heat, pain, redness, 
and swelling of the udder.  Cows may also suffer systemic symptoms of illness from 
mastitis, such as marked reductions in milk production, lack of appetite, fever, 
lethargy, weakness, dehydration, and diarrhea.  Most cases of mastitis, however, are 
asymptomatic or subclinical in nature and require a test to evaluate the number of 
leucocytes or somatic cell count (SCC) present in the milk.  Somatic cell counts of 
milk from normal or uninfected quarters has less than or equal to 100,000 cells.  A 
SCC of 200,000 or greater is defined as being subclinically infected (Smith, 2001).    
A California Mastitis Test (CMT) may be performed cow side to evaluate the SCC in 
each quarter and the probability of infection.  This involves stripping milk from each 
quarter into a separate well of a CMT paddle, adding CMT reagent to the milk, 
mixing the regent and milk, and visually scoring the degree of gelling displayed by 
the milk-regent mixture within 20 seconds.  CMT scores of Negative, Trace, 1, 2, and 
3 correspond with SCC of 100,000 or less, 300,000, 900,000, 2.7 million, and 8.1 
million (University of Wisconsin Milk Quality, 2011). .  Prognosis for eliminating the 




age of the cow and other host and environmental factors.  Mastitis may permanently 
damage the udder, reduce milk synthesis and quality, decrease fertility, and in severe 
cases, cause death (Harmon, 1994). 
 
Causative Agents  
Bovine mastitis is primarily caused by bacterial pathogens.  Bacterial species 
capable of causing mastitis are varied.  Staphylococcus spp., in particular S. aureus, 
Streptococcus spp., especially Streptococcus agalactiae, and Escherichia coli are 
among the most common major bacterial pathogens (Contreras et al., 2011; Wilson et 
al., 1997).  However, non-bacterial causative agents exist, such as viruses like 
herpesvirus, certain species of algae like Prototheca spp., and yeasts (Contreras et al., 
2011).   Incidences of non-bacterial associated mastitis are relatively low (Contreras 
et al., 2011; Wilson et al., 1997).    
 
Various Types of Mastitis  
Bovine mastitis is classified based on symptoms, source of infection, and 
course of infection.  In terms of symptoms, there is both clinical and subclinical 
mastitis.  Clinical mastitis tends to be acute and have obvious clinical symptoms, such 
as inflammation of the udder and altered milk appearance.  Subclinical mastitis cases 
are asymptomatic.  Despite the lack of symptoms, milk production and quality are 
reduced.  As for sources of infection, mastitis-causing agents are classified as either 
contagious or environmental.  Contagious pathogens are those that are directly passed 




hands.  Environmental pathogens are those that exist in the cow’s housing and 
environment and are transferred to the cow as it interacts with its environment.   
 
Treatments/Therapeutics  
Appropriate treatment of mastitis varies based on the mastitis causing agent, 
the form of infection, and whether the cow is lactating or not.  Generally, most 
antibiotic drugs will be administered through an intramammary route except in cases 
of acute, severe infection or coliform bacterial pathogens such as E. coli, in which 
parenteral administration is utilized to deliver fluids and anti-inflammatory drugs (du 
Preez, 2000; Barlow, 2011).  Depending on the route of administration, some 
antibiotics will better distribute across the udder than others (du Preez, 2000).  The 
most effective antibiotics will differ based on causative agent (du Preez, 2000).  Some 
antibiotics will only display activity against gram-positive or gram-negative bacteria.  
As mastitis has a variety of causative agents, it is important to tailor treatment to each 
case.   
 As compared with antibiotic therapy, during lactation, treatment of subclinical 
infections at dry-off with antibiotic products designed for dry cow therapy are more 
efficacious.   During lactation, organisms such as Staphylococcus spp., have low cure 
rates (du Preez, 2000).  Nevertheless, (J.E. Hillerton and E.A. Berry) recommend 
prompt treatment of all cases of clinical mastitis.  Antibiotics should be given 3 times 
in 12 hour intervals (du Preez, 2000).   In subacute mastitis infections, which have 
mild clinical symptoms and are often localized, the course of treatment is often 




always continue for 24 hours after clinical symptoms disappear (du Preez, 2000).  For 
acute mastitis infections, which have clinical symptoms with rapid onset and 
resolution, parental administration is recommended as antibiotics delivered through 
intramammary administration may fail to disperse throughout the udder tissue (du 
Preez, 2000).   Treatment usually lasts 3-5 days (du Preez, 2000).  Peracute infections 
are the most severe clinical infections and often result in the cow’s death.  They have 
largely the same treatments, but require greater monitoring of the cow’s condition to 
avoid shock and death (du Preez, 2000).  If a quarter becomes gangrenous, teat 
amputation is recommended (du Preez, 2000).  Permanent organ damage is a 
possibility after infection is resolved, so tying off the mammary vein is suggested to 
prevent bacterial toxins entering the bloodstream (du Preez, 2000).  If the cow 
develops a chronic mastitis infection, it is best to destroy infected quarters or cull the 
cow as cure rates are very low (du Preez, 2000).   
 
Cost to Dairy Industry  
Losses resulting from bovine mastitis cost the U.S. dairy industry $2 billion 
annually.  Economic losses for mastitis per a cow are $184.40 per a cow annually 
(National Mastitis Council, 1996).  Reduced production accounts for $121 of these 
losses.  The average production loss is 1,600 pounds per a quarter (National Mastitis 
Council, 1996).  However, losses are better estimated by SCC.  An increase from 
50,000 SCC per ml to lactation average of 100,000 SCC per mL-1 in the first lactation 
results in a 200-pound decrease in annual milk production (National Mastitis Council, 




production loss by an additional 200 pounds.  For example, production losses for 
cows with SCC averaging 100,000, 200,000, 400,000, and 800,000 are associated 
with production losses of 200, 400, 600, and 800 pounds per lactation, respectively. 
Production losses at each respective lactation average SCC of second and greater 
lactation cows are two-fold (National Mastitis Council, 1996) those of primiparous 
cows.   After a mastitis case, future lactations can also suffer from a reduced milk 
yield (Halasa et al., 2007; Hortet et al., 1998).  The remainder of economic losses are 
from discarded milk ($10.45), replacement cost ($41.73), extra labor ($1.14), 
treatment ($7.36), and veterinary services ($2.72) (National Mastitis Council, 1996).        
     
 
S. aureus 
General Information  
S. aureus is gram positive bacteria, which grows in cocci.  It can cause a wide 
range of diseases, depending on where in the host body it colonizes, but it is best 
known for skin infections.  Discovered in 1800, Alexander Ogston, a Scottish 
surgeon, found it in pus taken from a knee joint surgical abscess.  However, the 
species was not named and differentiated from others in the Staphylococcus genera 
until 1884 by Julius Rosenbach, a physician from Germany.     
 S. aureus is a fairly ubiquitous bacterium, living on the skin and in the noses 
of 25% of people.  However, in addition, to being a pathogen of humans and cattle, it 
can infect a wide variety of animals, including most pet and livestock species (Weese, 




mucosa, allowing S. aureus entry into deeper tissues or into the bloodstream (Lowy, 
1998; Lui, 2009).  S. aureus can infect a variety of locations, such as the skin, bones, 
joints, blood vessels, respiratory tract, and gastrointestinal tract (Lowy, 1998).  
Severity of the infection is variable, but it can be responsible for life-threatening 
diseases, such as bacteremia, endocarditis, sepsis, and toxic shock syndrome (Lowy, 
1998).   
  
S. aureus Associated Mastitis  
S. aureus is a contagious mastitis pathogen.  It is normally transferred to cattle 
from infected cows to uninfected cows through fomites that have been in contact with 
S. aureus infected milk.  These include the milking machine, human handlers, 
sponges, and towels.  S. aureus is a major mastitis pathogen, which is a pathogen that 
invades the entire mammary gland, as opposed to a minor pathogen, which colonizes 
only the teat end (Reyher et al., 2012).  Infection begins with S. aureus colonizing the 
teat orifice (Dego et al., 2002).  From there, S. aureus can continue colonization into 
the teat canal or be carried into the teat canal from pressure changes in the udder after 
the milking process (Dego et al., 2002).  When S. aureus contacts the milk, it can 
spread further into the udder, particularly during pressure changes in the udder (Dego 
et al., 2002).  S. aureus can then adhere to the surface of mammary epithelial cells 
and invade into them (Dego et al., 2002).  The invasion into cells allows S. aureus to 
evade the host immune response (Dego et al., 2002).     
In the 1960s and 1970s, S. aureus was the predominant mastitis-causing 




contagious mastitis pathogens, the United Kingdom began recommending the five-
point plan to farmers in the 1960s, which consisted of “1) post-milking teat 
disinfection; 2) total dry cow therapy; 3) therapy of clinical cases during lactation; 4) 
proper maintenance of milking machine; and 5) culling problem cows” (National 
Mastitis Council, 2006).  These practices were successful at reducing S. aureus 
associated mastitis infections in dairy herds as well as other gram-positive contagious 
mastitis pathogens (Neave et al., 1969; Philpot, 1978).  This was further expanded to 
a ten-point plan by the National Mastitis Council (2006), which included “1) 
Establishment of goals for udder health. 2)Maintenance of a clean, dry, comfortable 
environment. 3) Proper milking procedures. 4) Proper maintenance and us of milking 
equipment. 5) Good record keeping. 6) Appropriate management of clinical mastitis 
during lactation. 7) Effective dry cow management. 8) Maintenance of biosecurity for 
contagious pathogens and marketing of chronically infected cows. 9) Regular 
monitoring of udder health status. 10) Periodic review of mastitis control program”.  
Currently, the prevalence of contagious pathogens tends to be low (Shum et al., 
2009).  However, of the contagious pathogens, S. aureus is the most prevalent 
(Animal and Plant Health Inspection Service, 2008).         
 
Treatment of S. aureus Associated Mastitis  
S. aureus associated mastitis is generally treated with intramammary infusions 
of antibiotics for 3 days during lactation therapy.  Dry cow therapy, which involves 
treatment of antibiotics when the cow is no longer lactating, is often used in cases of 




aureus associated mastitis has a highly variable cure rate.  However, a study on 
heifers from the Netherlands exhibiting clinical symptoms shows a cure rate of about 
52% (Sol et al., 2000).  Subclinical mastitis cases suffer from a variable cure rate, 
ranging from 4% to 92% (Barkema et al., 2006).  When therapy was administered 
during lactation, the average cure rate was 34.4% for penicillin-sensitive S. aureus 
(Sol et al., 1997).  The average cure rate for S. aureus increased when dry cow 
therapy when utilized, but was still only 65.8% (Sol et al., 1994).  However, these 
cure rates are largely dependent on a combination of host, pathogen, and treatment 
factors.   
Host factors that reduce cure rate include higher parity, rear quarter infection, 
more affected quarters, higher colony forming units (CFU), and higher SCC 
(Barkema et al., 2006; Deluyker et al., 2005; Dingwall et al., 2003; Osteras et al., 
1999; Sol et al., 1994; Sol et al., 1997).   Higher parity may reduce cure rate for a 
variety of reasons.  First, older animals are more prone to disease and infection in 
general (Barkema et al., 2006).  Second, older cows have larger mammary glands, 
making it more difficult for antibiotics to diffuse within them (Barkema et al., 2006).  
Lastly, older cows tend to have more penicillin resistant mastitis infections (Barkema 
et al., 2006, Sol et al., 2000).  The infection of multiple quarters poses the risk of 
reinfection if not all quarters are cured (Barkema et al., 2006; Zadoks et al., 2001).   
In addition, rear quarters often yielded higher SCC and more frequent isolation of 
pathogens, making them more difficult to successfully treat (Barkema et al., 1997; 




The main bacterial factor to antibiotic susceptibility is strain.  Different strains 
have different transmission rates and manifestations, which is attributable to different 
genes controlling antibiotic resistance, intracellular survivability, biofilm formation, 
and host immune system evasion (Barkema et al., 2006).  Treatment can be 
complicated further by the fact that while infected herds may have one main strain, 
there are often other strains present (Barkema et al., 2006; Zadoks et al., 2000).  
Antibiotic resistance rates for S. aureus strains involved in mastitis tend to be highly 
variable between countries and geographical regions, but the presence of antibiotic 
resistance makes some mastitis strains more difficult to treat than others (Barkema et 
al., 2006).  In one study on dairy herds in New York, ampicillin, erythromycin, and 
penicillin resistance was found on both conventional and organic farms (Tikofsky et 
al., 2003).  Erythromycin resistance was the most common with it being found in 
50.4% of isolates in conventional farms and 44.4% of isolates in organic farms 
(Tikofsky et al., 2003).  However, both ampicillin and penicillin resistance were 
found at high rates as well.  Rates of ampicillin resistance were found to be 38.5% on 
conventional farms and 19.4% on organic farms (Tikofsky et al., 2003).  This is 
similar to the rates of penicillin resistance, which were 34.2% on conventional farms 
and 20.1% on organic farms (Tikosky et al., 2003).   Interestingly, resistance to one 
antibiotic seems to be correlated to antibiotic therapy resistance in vivo.  For example, 
penicillin-resistant strains of S. aureus have lower cure rates even when treating with 
other classes of antibiotics (Barkema et al., 2006; Sol et al., 2000).  Biofilm 
production also plays a larger part in therapy resistance and chronic infection.  S. 




isolates obtained from teat skin or milking unit liners (Fox et al., 2005).  It has been 
suggested that biofilm formation plays important part in establishing infection 
through greater adhesion and attachment to tissues (Fox et al., 2005).  These biofilms 
can also serve to maintain infection as biofilms have been shown to protect bacteria 
from the host immune response and be highly resistant to antimicrobials due to the 
exopolysaccharide slime covering the bacteria within a biofilm (Melchior et al., 
2006).        
  Treatment factors for cure rates are the types of antibiotics used, duration of 
use, method of administration, and point in lactation cycle that therapy is 
administered (Barkema et al., 2006).   Generally, higher cure rates were seen when 
drug combinations were used and therapy was extended to 5 or 8 days (Barkema et 
al., 2006).   
Whether it is economically justified to treat S. aureus associated mastitis 
depends on all these host, bacterial, and treatment factors (Barkema et al., 2006; 
Swinkels et al., 2005).   
 
Alternative Therapies 
As S. aureus associated mastitis is difficult to treat, there have been many 
studies that have looked at alternatives to antibiotics.  The most studied alternative 
therapies are bacteriocins, bacteriophages, vaccines, and genetic modification.  
Bacteriocins are antimicrobial peptides produced by other bacteria.  However, these 
generally run into similar issues to antibiotics, such as low cure rates (Barkema et al., 




infect bacteria.  When used for mastitis, they have low efficacy (Gill et al., 2006) and 
extreme host specificity.  Vaccinations are commercially available and many more 
have been studied.  However, none provide complete protection against infection or 
disease (Pereira et al., 2011).  They only increase efficacy of antibiotic treatment and 
decrease SCC (Barkema et al., 2006).  In addition, vaccines may be strain specific 
and fail to protect against a broad range of S. aureus strains (Barkema et al., 2006).  
Lastly, genetically modification has the potential to produce cattle that are resistant to 
mastitis and S. aureus infection (Wall et al., 2005).  However, public opinion on 
genetically modified organisms (GMO) is controversial and often polarized into pro- 
and anti-GMO interest groups, so commercial production of GMO animals is not 





The exact composition of orange oil is difficult to pinpoint (Shaw et al., 
1974).  There is a wide variety of components, each making up small fractions of the 
oil.  In addition, composition tends to change depending on when the orange was 
harvested in the year (Shaw et al., 1974).  Terpenes, however, make up the majority 
of the essential oil.  Of these, limonene is the most abundant terpene in orange oil, 
making up 93-96% of the oil (Azer et al., 2011; Shaw et al., 1974; Verzera et al., 
2004).  The abundances of the rest of the terpenes are normally below 1%, but they 




example, linalool is said to make up 0.3-0.8% of orange oil (Azer et al., 2011; Shaw 
et al., 1974; Verzera et al., 2004), and citral is said to make up another 0.25-0.65% 
(Shaw et al., 1974; Verzera et al., 2004).  There are other kinds of compounds 
present, but in much lower abundance, including alcohols, esters, aldehydes, 
hydrocarbons, ketones, and oxides (Azer et al., 2011; Verzera et al., 2004).  However, 
many microbiological studies use terpeneless, cold-pressed Valencia orange oil.  The 
composition of terpeneless orange oil is quite different.  One study found the 
composition of terpeneless, CPV orange oil to be 20.2% linalool, 18.0% decanal, 
9.1% geranial (which is a form of citral), 5.8% α-terpineol, 5.2% valencene, 5.0% 
neral (which is another form of citral), 4.1% dodecanal, 3.9% citronellal, and 0.3% 
limonene (Nannapaneni et al., 2009).       
 
Antimicrobial Activity  
Many essential oils have been studied for their antimicrobial properties, 
normally in relation to food safety.  Orange oil, whether whole or terpeneless, has 
been shown to strongly inhibit Salmonalla enterica (Dabbah et al., 1970; O’Bryan, 
2008), Escherichia coli (Dabbah et al., 1970), S. aureus (Dabbah et al., 1970; 
Muthaiyan et al., 2012), and Pseudomonas species (Dabbah et al., 1970), 
Campylobacter jejuni (Nannapaneni et al., 2009), Campylobacter coli (Nannapaneni 
et al., 2009), Arcobacter species (Nannapaneni et al., 2009).  The addition of orange 
oil in milk has been shown to increase shelf life, illustrating its antimicrobial ability 




orange oil, particularly citral and linalool, have demonstrated antimicrobial activity as 
well (Fisher et al., 2008; Kim et al., 1995). 
The mechanism for this antimicrobial action is not well understood.  The 
prevailing theory is that essential oils and their components can penetrate the bacterial 
cell wall (Burt, 2004; Fisher et al., 2008). This leads to an increase in cell 
permeability, resulting in leakage of cytoplasmic components, ions, and nutrients, 
which leads to cell death (Bakkali et al., 2008; Burt, 2004; Fisher et al., 2008).  Tea 
tree oil has been demonstrated to cause potassium ion leakage in S. aureus, which 
interferes with critical cellular processes (Fisher et al., 2008).  Through electron 
microscopy, one study was able to illustrate how cold-pressed Valencia orange oil 
caused cell wall damage in methicillin-resistant S. aureus (Muthaiyan et al., 2012).  
 
As an Alternative to Antibiotics  
In 2012, the U.S. Food and Drug Administration (FDA) issues guidelines for 
the use of antimicrobial drugs in food-producing animals.  This guidance mainly 
targets production uses of antimicrobials, such as increasing feed efficiency or weight 
gain (FDA, 2012).  The concern is that the mostly unregulated use of antimicrobial 
drugs in food-producing animals could lead to antibiotic resistance for drugs used in 
both animals and people (FDA, 2012).  The FDA claims that antimicrobial use be 
limited to what is necessary for assuring animal health (FDA, 2012).  Unfortunately, 
antibiotic use for subclinical mastitis is mostly ineffective, so it may do more to 




alternative products would mean that medically-important antimicrobial drugs would 
not be at risk for developing resistance. 
 In addition, organic farming is more limited that conventional farming in how 
they can use antibiotics.  Organic dairy farmers are not allowed to withhold antibiotic 
treatment from cattle, but cattle cannot have their milk sold as organic for 12 months 
after treatment (U.S. Department of Agriculture [USDA], 2015).  This can result in a 
substantial loss due to milk unable to be sold.  An antibiotic alternative would allow 
organic dairy producers to continue selling organic milk as well as treat their cattle. 
 Orange Oil is listed as generally recognized as safe (FDA, 2014).  Any 
generally recognized as safe (GRAS) product can be used for human consumption, 
meaning it presents a very low risk to human health.  However, the FDA also allows 
use of GRAS products in animal feed as well (FDA, 2010).  Due to the low risk to 
health, orange oil should be a safe product to use for cattle.  In addition, the USDA 
allows any GRAS product to be used in the organic livestock production (2015).       
 
 
Goals and Objectives 
Due to rising rates of antibiotic resistance and low success rates of mastitis 
treatments, the goal study aimed to determine whether cheap natural plant products 
could be used as a treatment option.  There were two objectives to this study: 
1. Examine the effects of terpeneless, cold-pressed, Valencia (CPV) orange oil 
on Staphylococcus aureus, bovine mammary cells, and the interaction 




2. Determine the effects of the major components found in terpeneless, CPV 






Chapter 2: Terpeneless, Cold-pressed Valencia Orange Oil and 
its Effects on Staphylococcus aureus, Bovine Epithelial 
Mammary Cells, and Infection  
Abstract 
This experiment examines the effects of cold-pressed, terpeneless Valencia orange oil 
(CPV) on growth of Staphylococcus aureus, a major cause of contagious bovine 
mastitis, and invasion of bovine mammary cells (MAC-T).   To determine minimum 
inhibitory concentration, we utilized the broth dilution method, using CPV 
concentrations range from 0.0125% to 0.4% with two-fold dilutions. Growth 
inhibition was examined by adding 0.00%, 0.05%, 0.025%, 0.0125%, and 0.00625% 
CPV to 105 CFU ml-1 S. aureus in nutrient broth and enumerating colonies after serial 
dilution.  In a 96 well plate, S. aureus (107 CFU ml-1) was allowed to form a biofilm, 
treated with 0%, 0.025%, 0.5%, or 1% CPV and then was measured using a 
spectrometer.  Cytotoxic effect on immortalized bovine mammary epithelial cells 
(MAC-T) was also examined at various concentrations of CPV using an MTT assay. 
We observed that the minimum inhibitory concentration of CPV to inhibit the growth 
of S. aureus in vitro was 0.025% CPV. A time kill curve for CPV’s action on S. 
aureus over 4 h was generated.  CPV completely eliminated S. aureus after 3 h 
incubation at concentration of 0.25% or after 2 h incubation at concentrations of 
0.05%.  It was also observed that CPV had no effect on pre-formed biofilms except at 
a concentration of 0.05%, in which there was a modest reduction in the measured 




of MAC-T cells by S. aureus after a 1 h treatment with CPV.  CPV was able to 
increase cellular proliferation of MAC-T cells at concentrations up 0.05% and had no 
effect at a concentration of 0.1%.  Our data suggests that CPV should be considered 
for further research as a preventative measure against or treatment of bovine mastitis.      
     
 
Introduction 
Mastitis, an inflammation of the mammary gland, is one of the costliest 
diseases impacting dairy farming, exceeding $2 billion annually, with economic 
losses resulting from premature culling, additional labor, management and veterinary 
costs, and reduced milk production and quality (Seegers et al., 2003; Bar et al., 2008). 
This cost excludes irreversible damage to the mammary gland that can lead to future 
reduced milk production, milk composition changes, and reproductive inefficiency 
from cows with mastitis (Harmon, 1994).   
Mastitis is characterized by an increase in milk somatic cell count (SCC) and 
may be accompanied by the presence of an intramammary pathogen (Paape et al., 
2003). Staphylococcus aureus is a major mastitis pathogen, meaning it infects the 
entire udder rather than solely the teat canal (Reyher et al., 2012).  Major mastitis 
pathogens, such as S. aureus, are considered as more virulent and damaging causative 
agents than minor mastitis pathogens, which only affect the teat canal (Reyher et al., 
2012).  Current management practices have greatly decreased prevalence of S. aureus 
and other contagious pathogens.  However, it is still one of the more common 




Tenhagen et al., 2006).  In addition, S. aureus is one of the most common contagious 
mastitis-causing agent (APHIS, 2008).  
Treatment of the causative bacteria using antibiotics is coming under 
increasing public scrutiny due to the possible development of resistant pathogens 
(Craven, 1987; Guterbock et al., 1993) and risk of residues appearing in the milk (De 
Vliegher et al., 2010).  One study, which included conventional dairy farms in New 
York, S. aureus resistance to ampicillin, erythromycin, penicillin, and tetracycline 
was found among isolates obtained from mastitic milk (Tikosky et al., 2003).  In 
addition, cure rates using antibiotics for S. aureus mastitis vary considerably ranging 
from 4 to 92% (Barkema et al., 2006).   A study on clinical mastitis cases in the 
Netherlands found a cure rate of only 52% (Sol et al., 2000).  For subclinical mastitis 
cases, cure rates were 34.4% for penicillin-sensitive S. aureus during antibiotic 
therapy during lactation (Sol et al., 1997) and 65.8% during dry cow therapy (Sol et 
al., 1994).  Thus, alternative strategies for control and treatment for S. aureus is 
essential for improving animal health and economic outcome for the farmer (Barkema 
et al., 2006).  
Many plant derivatives and essential oils derived from the citrus fruits and 
other plants contain secondary metabolites that can inhibit bacterial growth (Burt and 
Reinders, 2003; Burt, 2004). Essential oils, or fractions thereof, have been 
traditionally used as flavoring agents in foods, and it has frequently been noted that 
many possess antimicrobial properties (Kim et al., 1995; Lis-Balchin and Deans, 
1997; Smith-Palmer et al., 1998; Alzoreky and Nakahara, 2003). Cold-pressed, 




methicillin resistant S. aureus (MRSA) (Muthaiyan et al., 2012).  Therefore, 
examining its use as an alternative to antibiotic therapy for mastitis is warranted.  To 
our knowledge, no studies have examined the toxicity of CPV on mammary epithelial 
cells for use as an alternative therapy for mastitis. Our objective was to determine the 
inhibitory effect of CPV on the growth of bovine pathogen S. aureus and its role in 
host cell, bovine mammary epithelial cells (MAC-T), - S. aureus interactions to 
explore the potential strategy to control bovine mastitis.  
 
 
Methods and Materials 
Bacterial Strains and Growth Conditions 
S. aureus (ATCC 29740) strain was used in this study.  This strain has been 
isolated from bovine mastitic milk.  Response time and infection rate of this S. aureus 
strain has been documented previously with consistent changes in onset and duration 
of the host response beginning as early as 56 h and continuing through 240 h. 
(Bannerman, 2009). Bacteria were maintained in nutrient broth or nutrient agar 
(Gibco, USA) and were grown for 18-24 h before use.  
   
 
Preparation of Orange Oil 
Terpeneless, cold-pressed Valencia orange oil was provided by Firmenich 




CPV in dimethylsulfoxide (DMSO, Sigma, USA) to a final concentration of 40% 
CPV.  However, for the pre-formed biofilm experiment, a 10% CPV in DMSO stock 
solution was needed due to orange oil evaporation.  The 10% stock solution was also 
used for detection of cytotoxicity.    
 
Determination of Minimum Inhibitory Concentration (MIC) 
The broth dilution method was used to determine the MIC of S. aureus 
(Muthaiyan et al., 2012b).  Concentrations of CPV ranging from 0.0125% to 0.4% 
CPV with half step dilutions were added to 24 well plates containing 105 CFU ml-1 of 
S. aureus. Plates were incubated overnight and MIC was determined as the lowest 
concentration of CPV inhibiting visual growth of bacteria in the wells of 24-well 
plate (Greinerbio-one, USA). This was confirmed by colony forming unit (CFU) 
assay. 
   
Growth Inhibition Assay 
Using a spectrometer, S. aureus was diluted 108 CFU ml-1 in nutrient broth 
(Difco, USA) by adjusting it to OD600 ~0.08-0.12.  This was further diluted to 10
5 
CFU ml-1, and placed in cell culture tubes.  S. aureus was treated with CPV at 
concentrations of 0.00%, 0.05%, 0.025%, 0.0125%, and 0.00625%.  For 4 h, the cell 
culture tubes were kept in a shaking incubator at 37°C.  We took 100 µl of S. aureus 
every 15 m for 1 h, then every 30 m for 1 h, and then every 60 m for a total of 4 h of 
incubation.  This was serially diluted and plated on to nutrient agar (Difco, USA).  





Inhibition of Pre-Formed Biofilms 
The ability of CPV to affect preformed S. aureus biofilms was performed, 
using methods adapted from Karaolis et al. (2005), O’Toole (2011), and Ma et al. 
(2012). Briefly, bacterial cells were inoculated into nutrient broth and incubated for 
18 h.  The OD600 of the bacterial suspension was adjusted to ~0.08-0.12 (10
8 CFU ml-
1) and then further diluted with nutrient broth to 107 CFU ml-1. Diluted cultures were 
aliquoted (200 µL) into a 96-well polystyrene flat-bottom microtiter plate 
(Greinerbio-one, USA) and incubated statically at 37°C for 24 h. Following 
incubation, the supernatant was removed and fresh nutrient broth (200 µL) containing 
0%, 0.025%, 0.05%, or 0.1% CPV was placed in the wells and wrapped with Parafilm 
(Sigma-Aldrich, USA) for an incubation interval of 24 h at 37°C. After incubation, 
the plate rinsed thrice with distilled water. Afterwards, 0.1% crystal violet (200 µL) 
was added, and the plate was incubated at room temperature for 10-15 m. The plates 
were rinsed thrice and allowed to air dry overnight. Aliquots of 200 μL 30% acetic 
acid in distilled water was used to dissolve the crystal violet, and plates were shaken 
for 1 h before being the solution in each well was transferred to a new 96-well plate. 
To determine biofilm growth, the absorbance was measured by a spectrophotometer 
(Thermo Scientific, USA) at 540 nm. 





Mammalian Cell Culture and Monolayer Formation 
The immortalized bovine mammary gland epithelial cell line (MAC-T) was 
maintained in 75 cm2 cell culture flasks in Dulbecco’s modified Eagle medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS) and 100 μg of 
gentamicin mL-1 at 37°C, 5% CO2.  
   
Inhibition Assay for S. aureus Association to and Invasion of MAC-T cells 
The adherence and invasion assay was modified from Biswas et al. (2000) and 
Salaheen et al. (2014).  In a 24 well plate, 105 MAC-T cells in 500 μL in Dulbecco’s 
modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) 
were seeded into each well and incubated for 24 h at 37°C, 5% CO2.  S. aureus was 
cultured and incubated for 18 h at 37°C.  S. aureus was then diluted to 108 CFU ml-1 
in nutrient broth by adjusting it to OD600 ~0.08-0.12 before being further diluted to 
107 CFU mL-1.  The wells containing MAC-T cells were then washed three times 
before being infected with 10 μL of 107 CFU mL-1 S. aureus and 1mL of DMEM 
supplemented with 10% FBS.  The plates were incubated for 1 h at 37°C with 5% 
CO2 to allow time for infection.    Wells are then washed thrice with DMEM, and 
then treated with DMEM supplemented 10% FBS and 0%, 0.025%, 0.05%, 0.1%, or 
0.2% CPV.   The plates were incubated again for 1 h at 37°C, 5% CO2.  To measure 
association to MAC-T cells, the cells were washed three times with DMEM, treated 
with 0.1% Triton X-100, and incubated for 15 m at 37°C, 5% CO2.  Associated 
bacterial cells were then serial diluted and plated for enumeration.  To measure 




with 10% FBS and 100 μg of gentamicin/mL for 1 h at 37°C, 5% CO2 before the 
following the same procedure to measure association.   
 
  Detection of Cytotoxicity of Orange Oil on MAC-T cells 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay methods were adapted from Murbarak et al. (2015) and Yousefzadi et al. 
(2011).  From an initial cell suspension of 2x105 MAC-T cells, 200 µL of this 
suspension was added into each well, for a final cell population of ~ 4x104 cells/well 
into a round bottom 96 well plate and incubated for 24 h at 32°C, 5% CO2. The media 
was removed, and cells were washed three times with DMEM before media was 
replaced with 200 µL DMEM supplemented with 10% FBS, 100 μg of gentamicin 
mL-1, and 0%, 0.025%, 0.05%, or 0.1% CPV. This plate was incubated for 1 h at 
37°C, 5% CO2. Media was removed again, and the cells were washed three times 
with DMEM before 200 μL of DMEM supplemented with 10% FBS and 100 μg mL-1 
gentamicin was added to each well with 20 μL of 5 mg mL-1 MTT, reconstituted in 
1x PBS.   The cells were incubated for 2 h to allow reduction of MTT at 37C, 5% 
CO2. Lysed cells will not react with MTT.  Afterwards, media was removed and 200 
µL of DMSO was added to each well.  The 96 well-plate was incubated for 10-15 m 
with shaking before reading at an absorbance of 570 nm.  A blank of 100% DMSO 






Two-way ANOVA analysis and Tukey’s HSD was carried out using the 
general linear model in Statistical Analysis System® (SAS, Cary, North Carolina) 
statistical significance between trials.  Results were considered statistically significant 




Minimum Inhibitory Concentration of CPV 
The growth of S. aureus was inspected after treatment of CPV at 
concentrations ranging from 0.0125% to 0.4% for 18 to 24 h.  For S. aureus, the 
minimum inhibitory concentration was 0.025% CPV during an 18-24 h period as 
determined by visual inspection.   
 
Growth Inhibition of S. aureus by CPV 
 S. aureus growth was reduced most of CPV concentration and time point 
except incubated in medium containing 0.00625 % and 0.0125% CPV for 15 min 
(Figure 1). All CPV trials were capable of significant reductions in S. aureus bacterial 
cell count, but the magnitude and speed of this inhibitory action depended on 
concentration.  After only 15 min, the 0.05% CPV trial and 0.025% CPV trial created 
statistically significant reductions compared to the DMSO trial with an average of 




4.78 ± 0.35 log CFU ml-1 in the DMSO control.  After 30 min, the bacterial counts 
0.0125% CPV reduces to at 4.1126 ± 0.62 log CFU ml-1, which is statistically 
significant decrease in bacterial count the DMSO control at 4.82 ± 0.26 log CFU ml-1.  
At the lowest concentration used of 0.00625% CPV, the numbers of S. aureus were 
reduced from 4.98 ± 0.14 log CFU ml-1 to 4.15 ± 0.21 log CFU ml-1 over the 4 h time 
period.  This reduction begins around 60 m of exposure, when numbers of S. aureus 
are 4.78 ± 0.05 log CFU ml-1, which is statistically significant from the DMSO 
control trial at 5.02 ± 0.22 log CFU ml-1.  All trials show further reduction at every 
following interval.  Some concentrations were able to effectively eliminate S. aureus 
below detectable limits.  At a concentration of 0.025% CPV, no S. aureus was 
recovered after 180 m and at a higher concentration of 0.05% CPV, no S. aureus was 
recovered after 120 m.  However, S. aureus was only reduced to 2.70 ± 0.12 log CFU 
ml-1 at a concentration of 0.0125% after 4 h.  Lower concentrations also failed to 
eliminate S. aureus below detectable limits. 
 
Effect of CPV on Pre-Formed Biofilms 
CPV’s effect on preformed S. aureus biofilms is shown in Figure 2.  These 
biofilms were formed in 96 well plates over 24 h before being treated with CPV for 
another 24 h.  Concentrations of CPV used were 0%, 0.025%, 0.05%, and 0.1% in 
nutrient broth.  Absorbance in each well was measured at 540 nm.  There was no 
statistical difference in absorbance in biofilm growth between 0% CPV, the control, 




difference in biofilm growth between 0.05% CPV (A540 0.056) and the control (A540 
0.061).   
      
Cytotoxicity of CPV on MAC-T cells 
CPV has no cytotoxic effect on MAC-T cells, which is displayed in Figure 3.  
This was measured after 1 h of treatment.  CPV concentrations start at 0.025% with 
half step dilutions up to 0.1%.  At the lowest concentrations, CPV was able to 
increase proliferation.  Relative cytotoxicity was measured -38.0% for 0.025% CPV 
and -42.2% for 0.05% CPV.  However, at the highest concentration, 0.1%, there was 
no effect on MAC-T cells.  The relative cytotoxicity measured for 0.1% CPV was -
13.5%, which was not significant difference from the baseline.   
 
Inhibition of S. aureus Association to and Invasion of MAC-T cells 
Figure 4 displays quantities of S. aureus recovered from MAC-T cells after 
CPV treatments.  S. aureus with MAC-T cells were treated for 1 h with range of CPV 
conditions starting at 0.2% with half step dilutions down to 0.025% and a control 
using DMSO.  Associated bacteria are those adhered to and invaded in host cells.  
CPV had an effect on association of S. aureus to MAC-T cells at the highest 
concentrations tested.  No bacterial cells were recovered after treating with 0.1% and 
0.2% CPV for 1 h.  These results were statistically significant at p<0.05.  
Adhesiveness of S. aureus to MAC-T cells was 46% and 70% reduced in 0.025 and 
0.05% CPV treated group compared with the non-treated control, respectively (Figure 




CPV was shown to inhibit invasion of S. aureus specifically as well.  A bar graph 
depicting this data is displayed in Figure 5.  The concentrations of CPV tested were 
identical to those used in the association assay.  Concentrations as low as 0.025% 
CPV were capable of inhibiting invasion by S. aureus.  There was significant 
difference between the control of 0% CPV and all the CPV treatments.  For S. aureus 
in 0.025% CPV, bacterial count decreased from 2.34 x 104 CFU mL-1 to 6.17 x 102 
CFU mL-1.  At a concentration of 0.5% CPV, recovered S. aureus decreased to 1.00 x 
102 CFU mL-1. At concentrations of 0.1% CPV and above, S. aureus was no longer 




The effects antimicrobial effects of citrus derived oil have been well-
documented, but most studies have focused on its effects on foodborne pathogens.  
This study aimed to test the antimicrobial properties of CPV on a common mastitis-
causing pathogen, S. aureus. The strain of S. aureus used was isolated from the milk 
of cows with mastitis as opposed to strains found in foodborne infection.  However, 
studies done on foodborne strains of S. aureus suggest CPV will be effective against 
S. aureus strains associated with mastitis as CPV acts on the cell wall of the bacteria 
(Muthaiyan et al., 2012b).   
In this study, we investigated antimicrobial properties of CPV on S. aureus 
and it was fast and effective.  We identified that MIC of CPV was 0.025% on growth 




has been shown for other strains of S. aureus (Muthaiyan et al., 2012b).  However, 
the MIC for S. aureus is variable depending on strain with another study reporting an 
MIC of 0.5% (Espina et al., 2011).  Even low concentrations of CPV, such as 
0.00625%, also inhibited S. aureus growth in a time kill curve assay. CPV inhibited 
S. aureus growth in all CPV treatments compared with a 1% DMSO treatment.  S. 
aureus was eliminated below detectable limits in medium containing 0.025% and 
0.05% CPV after 180 min and 120 min incubation, respectively (Figure 1). This is 
consistent with findings in another study that showed a 0.1% concentration of orange 
oil and orange terpeneless oil was effective at S. aureus growth by 100% (Dabbah et 
al. 1970) as elimination of S. aureus below detectable limits occurs at 0.025% CPV or 
higher.  There are various proposed mechanisms of action.  The first is that the 
essential oils cause damage to the cell well (Burt, 2003; Helander et al., 1998; 
Muthaiyan et al., 2012b).  The second is the essential oils cause damage to the cell 
membrane and mitochondrial membrane (Burt, 2004).  This is due to the fact the 
essential oils tend to be hydrophobic, so they disrupt the membrane, increasing 
membrane permeability (Burt, 2004; Fisher et al., 2008).  The third is that essential 
oils damage membrane proteins (Burt, 2004).  All of these mechanisms can result in 
leakage of ions and nutrients out of the cell (Burt, 2004; Fisher et al., 2008).   
The effect of CPV on preformed S. aureus biofilms was tested.  S. aureus 
biofilms play a role in chronic and recurrent mastitis infections, allowing the infection 
to hide from antimicrobials (Melchior et al., 2006).  To our knowledge, no other study 
has examined the effect of CPV alone on S. aureus biofilms.  However, other 




epidermis biofilms (Solórzano-Santos et al., 2012).  In addition, one study had used a 
1:1 blend of orange oil and bergamot oil to inhibit S. aureus (Laird et al., 2012).  
There were modest reductions in organisms after a 24 h exposure (Laird et al., 2012).  
After growing biofilms for 18-24 h, CPV treatment was applied, and then the 
absorbance at OD570 was measured.  CPV was shown to only have a modest effect on 
biofilms at a concentration of 0.05%, but no effect at 0.025% and 0.1%. This is 
similar to the action of some antibiotics on biofilms (Kaplan, 2011).  Induction of 
biofilms is often seen at low doses, and occasionally, at high ones as well, creating a 
u-shaped dip in which the antibiotic is most effective (Kaplan, 2011).  Low doses of 
antibiotics are capable of inducing transcription with about 5% of bacterial promoters 
being upregulated during exposure (Kaplan, 2011).  Notably, biofilm formation 
appears to be upregulated by some low doses of antibiotics in some bacteria, such as 
rifampin on S. epidermis (Kaplan, 2011).  It is possible that orange oil is acting in a 
similar manner to antibiotics and is inducing transcription of biofilm genes at lower 
concentrations.  High doses stimulation is also seen in other bacteria during high dose 
antibiotic exposure (Kaplan, 2011).  As CPV is a modest inhibitor preformed 
biofilms, it may be unable to limit chronic cases of mastitis except when used in 
moderate doses. 
We then used MAC-T cells for an in vitro model of CPV’s effect on S. aureus 
in a mammary gland.  Inhibition of association was tested.  Association measures 
adherence as well as invasion.  Infection by S. aureus begins with adhesion to bovine 
mammary gland cells, and adherence is the initial step in pathogenesis (Dego et al., 




association by S. aureus to MAC-T cells (Figure 3).  Inhibition of invasion was then 
tested.  Chronic mastitis by S. aureus is a large problem, caused by invasion into the 
cell, since antimicrobials typically only affect extracellular bacteria (Barkema et al., 
2006). Therefore, treatments are needed which can prevent and inhibit intracellular 
invasion.  In MAC-T cells, it only took a concentration of 0.025% CPV to inhibit 
invasion by S. aureus significantly from 2.34 x 104 CFU ml-1 to 6.17 x 102 CFU ml-1.  
Higher concentrations resulted in greater reductions in bacterial count.  Other studies 
have documented orange oil’s ability to eliminate S. aureus from infected 
keratinocytes after using a concentration of 0.2% to treat cells (Muthaiyan et al., 
2012b).  Invasion of S. aureus into bovine mammary cells is thought to be caused by 
S. aureus producing factors which mobilize F actin microfilaments in the bovine cell 
cytoskeleton, allowing the bacteria to be internalized through endocytosis (Almeida et 
al., 1996).  Binding to fibronectin appears to be necessary and sufficient for adhesion 
as well as invasion (Menzies, 2003; Dego, 2002).  S. aureus has fibronectin binding 
proteins on the surface of the cell membrane (Menzies, 2003).  It is possible CPV 
disrupts fibronectin binding proteins, preventing endocytosis of S. aureus, but further 
study is required.   
Determination of any cytotoxic effect of CPV on bovine mammary epithelial 
cells is necessary to ensure safety if used in vivo.  Cytotoxicity of CPV was tested on 
MAC-T cells in order to model in vivo bovine mammary epithelial cells.  CPV does 
not have a cytotoxic effect on MAC-T cells.  Its proliferation stimulating effect at 
concentrations of 0.025% and 0.5% may even serve to reverse damage to udder tissue 




of CPV on bovine mammary cells.  However, there is a study, which found that CPV 
has no effect on mice macrophage cells at concentrations of 0.025% and 0.05% 
(Scelza et al., 2006).  From both of these studies, it does not appear that CPV negative 
impacts cell viability.   
In this study, we provided evidence that CPV has an antimicrobial effect on S. 
aureus.   Our data suggest that CPV has the potential to be a treatment for S. aureus 
mediated mastitis.  Other studies can be done to see whether CPV’s other effects on 
S. aureus, such as inhibition of the release of exotoxins, inhibition of autoaggregation, 
and hydrophobic action.  In addition, more work should be done to examine its 
antibiofilm properties, including its effects on biofilm growth across a greater range 
of concentrations as well as how it effects gene expression of biofilm genes.  To 
ensure its safety for cattle, more work must be done to determine CPV’s effects on 
MAC-T cells, such as cytokine production and milk synthesis.  Lastly, CPV should be 
researched on other causative agents of bovine mastitis to see its effects on other 
pathogens.     




Chapter 3: Major Components of Terpeneless, Cold-pressed 
Valencia Orange Oil and its Effects on Staphylococcus aureus, 
Bovine Epithelial Mammary Cells, and Infection 
Abstract 
 Bovine mastitis is a costly disease in the dairy industry that does not always 
respond to antibiotic treatment.  The major components of terpeneless, cold-pressed 
Valencia orange oil, citral, linalool, decanal, and valencene, were examined as 
potential alternative treatments for Staphylococcus aureus associated mastitis.  The 
minimum inhibitory concentration (MIC) of all four components against S. aureus 
was determined after 24 h incubation.  Growth inhibition assay was performed for all 
effective components on S. aureus for either a 3 h or 72 h treatment.  These 
components were tested for the ability to disrupt pre-formed S. aureus biofilms after 
24 h of treatment by measuring absorbances at 540nm.  Cytotoxicity against 
immortalized bovine mammary epithelial (MAC-T) cells was measured using MTT 
assay following a 1 h exposure.  Only concentrations below the 50% cytostatic 
concentration (CC50) were used in an adherence and invasion assay of S. aureus on 
MAC-T cells and measurements of gene expression for virulence and biofilm genes 
via qPCR.  The MICs of citral and linalool were 0.02% and 0.12%, respectively, but 
decanal and valencene were ineffective.  Citral and linalool were capable of inhibiting 
growth of S. aureus after 24 h at their MIC values and inhibited pre-formed biofilms 
of S. aureus.  The concentrations below CC50 were 0.02% for citral, and 0.12% for 




aureus and downregulated virulence genes.  Only 0.12% linalool was enough to 
downregulate the expression of S. aureus biofilm forming genes.  These components 




Bovine mastitis is inflammation of the udder tissue in at least one quarter and 
is usually caused by a bacterial pathogen (Contreras et al., 2011; Wilson et al., 1997).  
However, treatment for bovine mastitis can be expensive depending on the type of 
infection.  On a national level, the US dairy industry loses $2 billion in costs 
associated with mastitis each year (National Mastitis Council, 1996).  On a farm 
level, the cost per a cow can vary depending on severity and chronicity of infection.  
Symptoms of clinical mastitis may include localized swelling and redness of one or 
more udder quarters and in more severe cases, systemic signs of depression, anorexia, 
fever, and reduced milk quality and production.  Clinical cases of mastitis cost $179 
per a cow (Bar et al., 2008).  Yet, subclinical cases are more prevalent (Barlow, 2011; 
Haveri et al., 2005).  Subclinical cases may only present with reduced milk quality 
and production as well as an elevated somatic cell count (SCC).  With a medium 
SCC, subclinical cases of mastitis cost $108 per a cow (Ott, 1999).  However, 
subclinical cases with high SCC can cost dairy producers $295.24 per a cow (Ott, 
1999).  In addition to economic losses, mastitis can have a long term impact on the 




mammary tissue, which reduces milk production and quality for a lifetime, and 
decreased reproductive efficiency (Harmon, 1994).   
Staphylococcus aureus is an infectious bacterial pathogen, which is usually 
spread between cows during the milking process.  The most common form of 
treatment is antibiotic therapy.  However, antibiotics often fail to cure S. aureus 
associated mastitis, particularly in subclinical and chronic cases (Barkema et al., 
2006).  This combined with pressure from the FDA as well as consumers to reduce 
antibiotic usage makes it urgent to search for alternative in the treatment of mastitis.    
Essential oils have been studied for their antimicrobial properties (Kim et al., 
1995; Lis-Balchin and Deans, 1997; Smith-Palmer et al., 1998; Alzoreky and 
Nakahara, 2003).   One commonly studied essential oil is orange/citrus oil.  Orange 
oil has been demonstrated to inhibit methicillin resistant S. aureus (MRSA) growth 
(Muthaiyan et al., 2012).  Since it is a generally recognized as safe product, the FDA 
allows its use in human and animal feed.  In addition, it can be cheaply extracted, 
making it a cost effective antimicrobial product.  However, orange oil contains many 
compounds of which do not have antimicrobial properties.  The major components of 
terpeneless, cold-pressed Valencia orange oil as being 20.2% linalool, 18.0% decanal, 
14.1% citral, 5.8% α-terpineol, 5.2% valencene, 4.1% dodecanal, 3.9% citronellal, 
and 0.3% limonene (Nannapaneni et al., 2009).  Both linalool and decanal have 
demonstrated inhibition of S. aureus growth (Liu et al., 2012).  Citral has been 
studied for its ability to inhibit a wide range of bacterial pathogens, such as S. aureus, 
as well pathogenic fungi (Saddiq et al., 2010).  As a result, these compounds are of 




In this study, we aimed to investigate the potential role of the most prevalent 
components of cold-pressed, terpeneless Valencia orange oil, linalool, decanal, citral, 
and valencene as an antibiotic alternative in the treatment of S. aureus associated 
bovine mastitis.  Their interaction with S. aureus and bovine mammary epithelial 
(MAC-T) cells was examined.    
 
 
Methods and Materials 
Bacterial Strains and Growth Conditions 
The S. aureus (ATCC 29740) strain, isolated from mastitic milk, was used for 
this study.  S. aureus was grown and maintained on nutrient agar or nutrient broth 
(Gibco, USA).  Prior to each experiment, S. aureus was sub-cultured on nutrient agar 
plate from the freezing (-80°C) stock and grown for 18-24 h at 37°C.   
 
Preparation of Orange Oil Components 
Citral, linalool, decanal, and valencene (Sigma-Aldrich, USA) were used for 
this study. A 10% stock solution for these components in 1% Tween-80 in distilled 






Determination of Minimum Inhibitory Concentration 
Minimum inhibitory concentration (MIC) was determined using the broth 
dilution method described by Muthaiyan et al. (2012b).  Concentrations of citral, 
linalool, decanal, and valencene ranging from 0.01% to 2.5% were tested for 
antimicrobial activity against S. aureus.  These concentrations were added to 105 CFU 
ml-1 of S. aureus in a 24 well plate (Greinerbio-one, USA).  S. aureus was incubated 
overnight at 37°C, and visually inspected for growth inhibition to determine the MIC.  
 
Growth Inhibition Assay 
S. aureus was diluted to 105 CFU ml-1 in LB or nutrient broth (Difco, USA) 
after being adjusted to OD600 ~0.08-0.12, which is equal to 10
8 CFU ml-1.  The LB or 
nutrient broth was either supplemented with 0.02% citral, 0.04% citral, 0.12% 
linalool, or 0.24% linalool.  A control was used, which contained unsupplemented LB 
or nutrient broth.  S. aureus was incubated for 72 h at 37°C in cell culture tubes, and 
enumeration took place every 24 h.  If no bacteria were detectable after 24 h for any 
concentration, the experiment was repeated except with incubation for 3 h and 
enumeration occurring every 1 h.   
 
Inhibition of Pre-Formed Biofilms 
Methods were adapted from literature previously described by Karaolis et al. 
(2005), O’Toole (2011), and Ma et al. (2012).  S. aureus was adjusted to 108 CFU ml-
1 by diluting to OD600 ~0.08-0.12.  This was then further diluted to 10
7 CFU ml-1.  




microtiter plate (Greinerbio-one, USA).  These plates were incubated statically for 24 
h at 37°C.  Supernatants of the 24-wells plate were the removed and discarded, and 
the biofilms were then treated with unsupplemented nutrient broth or nutrient broth 
supplemented with 0.02% citral, 0.04% citral, 0.08% citral, 0.12% linalool, 0.24% 
linalool, or 0.48% linalool.  These plates were sealed with Parafilm (Sigma-Aldrich) 
to prevent evaporation of citral and linalool and incubated for 24 h at 37°C.  
Supernatant was shaken out, and 96 well plates were rinsed by being submerged in 
water.   Plates were rinsed three times with water being shaken out after each rinse.  
Aliquots of 200 μL of 0.1% crystal violet was added to each biofilm and incubated 
for 10-15 min at room temperature.  The plates were then rinsed again three times 
with water being shaken out after each rinse, and allowed to dry overnight.  To each 
well, 200 μL of 30% acetic acid in distilled water was added.  Plates were shaken at 1 
h, and the acetic acid solution was added to a new plate.  The absorbances of the 
solution were then read at 540 nm using a spectrometer (Thermo Scientific, USA).       
 
Mammalian Cell Culture and Monolayer Formation 
The MAC-T cell line is an immortalized bovine mammary gland epithelial 
cell line and was used for all cell culture work.  These cells were maintained in 
Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS) and 100 μg of gentamicin mL-1 in 75 cm2 cell culture flasks and 





Detection of Cytotoxicity of Citral and Linalool on MAC-T cells 
Methods were adapted from Murbarak et al. (2015) and Yousefzadi et al. 
(2011) and used a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay for determining cytotoxicity.  Aliquots of 200 μL of a 2 x 105 MAC-T 
cell suspension into a 96 well plate.   This plate was incubated for 24 h at 32°C in a 
5% CO2 incubator. The media was removed, and the cells were washed three times 
with DMEM.  The cells were then treated with DMEM supplemented with 10% FBS, 
100 μg mL-1 gentamicin, and either 0.02% citral, 0.04% citral, 0.08% citral, 0.12% 
linalool, 0.24% linalool, or 0.48% linalool.  A control of only DMEM supplemented 
with 10% FBS, 100 μg mL-1 gentamicin was used as well.  The cells were incubated 
again for 1 h at 32°C in a 5% CO2 incubator.  Afterwards, the media was removed 
and cells were washed three times with DMEM.  Cells were then incubated with 200 
μL of DMEM supplemented with 10% FBS and 100 μg mL-1 gentamicin and 20 μL 
of 5 mg mL-1 MTT, reconstituted in 1x PBS for 2 h at 37°C in a 5% CO2 incubator.  
The media was then removed, and dimethylsulfoxide (DMSO, Sigma-Aldrich, USA).  
The 96 well-plate was shaken for 10-15 min.  The absorbance was read at 492 nm on 
a spectrometer with a blank of 100% DMSO.   
 
S. aureus Association and Invasion Assay for MAC-T cells 
The methods from Biswas et al. (2000) and Salaheen et al. (2014b) were 
adapted for this assay.  Aliquots of 500 μL of a suspension of 2 x 105 MAC-T cell 
mL-1 in DMEM supplemented with 10% FBS were added to a 24 well plate.  The 




were washed three times with DMEM, 1 mL of DMEM supplemented with 10% FBS 
was added to the cells, and 10 μL of 108 CFU ml-1 S. aureus, for a final concentration 
of 106 CFU mL-1 S. aureus, was used to infect the cells.  These cells were incubated at 
37°C in a 5% CO2 incubator for 1 h.  Afterwards, cells were washed three times with 
DMEM and treated with DMEM supplemented with 10% FBS and either 0.02% 
citral, 0.04% citral, or 0.12% linalool.  A control of only DMEM supplemented with 
10% FBS was used again.  The cells were incubated again for 1 h at 37°C in a 5% 
CO2 incubator.  Cells were then washed three times with DMEM.  To enumerate 
associated bacteria, cells were incubated with 0.1% Triton X-100 (Sigma, USA) for 
15 min at 37°C, in a 5% CO2 incubator, and the associated bacteria was plated on LB 
agar to count colonies.  To enumerate invaded bacteria, cells were first treated with 
DMEM supplemented with 10% FBS and 100 μg mL-1 gentamicin for 1 h at 37°C in 
a 5% CO2 incubator.  Afterwards, cells were incubated with 0.1% Triton X-100 
(Sigma, USA) for 15 min at 37°C in a 5% CO2 incubator, and the invaded bacteria 
was plated on LB agar to count colonies.            
 
Effect on Gene Expression of S. aureus Virulence and Biofilm Genes  
For gene expression of S. aureus virulence genes and MAC-T cells cytokine genes, 
MAC-T cells were infected and treated in a similar fashion to the association and 
invasion assay, but scaled up to 6 mL in 25cm2 flasks.  Afterwards, RNA was 
extracted using methods described in Ahn et al. (2014).  A NanoDrop ND-1000 was 
used to measure the concentration of extracted RNA.  A concentration of 1 μg of 




Synthesis Kit (Thermo Scientific, USA).  All quantitative PCR used the methods 
described in Ahn et al. (2014) and Salaheen et al. (2014), except cDNA was diluted 
10 fold.  The cytokine genes measured were IL-1β, IL-6, IL-8, TNFα, IFNγ, IL-12, 
and IL-17A with RPLP0 being used as a reference gene.  These cytokine genes and 
primers are listed in Table 1.  The virulence genes measured were agrA, sodA, sirA, 
hla, hlb, spa, sbi, sarA, sarR, sarS, and sigB, and the reference gene used was 
16sRNA.  The virulence genes and primers used in this study are listed in Table 2.  
To determine expression of S. aureus biofilm genes, S. aureus was formed and treated 
in the same way as the inhibition of pre-formed biofilms assay.  However, treatments 
only included a LB broth control, 0.02% citral, 0.04% citral, and 0.12% linalool.  
After 24 h of treatment, RNA extract, cDNA synthesis, and qPCR was carried out 
using the same methods described for the virulence genes above except cDNA 
synthesis used qScript cDNA SuperMix (Quanta Biosciences, USA).   The biofilm 
genes measured were icaA, icaB, icaC, icaD, fnbA, fnbB, clfA, clfB, and ebps and 
16sRNA was used a reference.  All biofilm genes are primers used are listed in Table 
3.   
 
Statistical Analysis 
Statistical significance between treatments was determined by two-way 
ANOVA analysis and Tukey’s HSD, using the general linear model in Statistical 
Analysis System® (SAS, Cary, North Carolina).  If p<0.05, mean differences were 






MICs of Citral, Linalool, Decanal, and Valencene Required to Inhibit S. aureus 
The MICs of citral, linalool, decanal, and valencene are shown in Table 4.  
Only citral and linalool were found to have an inhibitory effect on S. aureus.  The 
MICs for citral and linalool were 0.02% and 0.12%, respectively.  A concentration of 
2.5% was not even sufficient to inhibit growth of S. aureus for either decanal or 
valencene.  Due to higher MIC values and cytotoxic effects, decanal and valencene 
were excluded from the remainder of the study. 
 
Time Dependent Inhibitory Effects of Citral and Linalool on S. aureus Growth 
Growth inhibition of S. aureus by various concentrations of citral and linalool 
over 72 h is shown in Figure 6.  Concentrations of 0.04% citral and 0.24% linalool 
inhibited the growth of S. aureus below detectable limits after 24 h of treatment.  The 
minimum concentration, 0.02% citral, inhibited growth by 3.76 log CFU mL-1, and 
0.12% linalool inhibited growth by 2.67 log CFU mL-1.  The difference in inhibitory 
effect between citral and linalool after 24 h of treatment was not statistically 
significant.  This inhibitory effect was maintained for 72 h for both citral and linalool.  
However, the inhibitory effect was reduced after 48 h for both citral and linalool.   
A shorter 3 h growth inhibition assay was used for 0.04% citral and 0.24% 
linalool, which is shown in Figure 7.  A concentration of 0.04% citral decreased S. 
aureus concentration below that of the initial inocula after 1 h and eliminated S. 
aureus below detectable limits by 3 h.  A concentration 0.24% linalool also 




not decrease S. aureus concentration below that of the initial inocula until 3 h of 
treatment. 
  
Inhibition of Pre-formed S. aureus Biofilms with Citral and Linalool 
Figure 8 illustrates the inhibition of S. aureus pre-formed biofilms by both 
citral and linalool.  All concentrations tested, which included the MIC values above, 
were capable of inhibiting pre-formed biofilms.  The most effective concentrations 
were 0.08% citral, 0.24% linalool, and 0.48% linalool, which had absorbances of A540 
0.079, A540 0.075 and A540 0.067, respectively.  The difference in absorbance between 
these concentrations was not statistically significant.  However, this was significantly 
lower than the absorbances of the control and 0.02% citral, which were A540 0.104 
and A540 0.090, respectively.      
 
Cytotoxic Effects of Minimum Concentration of Citral and Linalool on MAC-T cells 
Cytotoxicity of the minimum concentration of citral and linalool on MAC-T 
cells are shown in Figure 9 and 10, respectively. Figure 9 represents the depicting 
relative cytotoxicity for citral and Figure 10 represents the depicting relative 
cytotoxicity for linalool.  Both citral and linalool showed cytotoxicity for all 
concentrations tested.  For citral, relative cytotoxicities for 0.02%, 0.04%, and 0.08% 
citral were 29.8%, 47.7%, and 59.6%, respectively.  For linalool, the relative 
cytotoxicities for 0.12%, 0.24%, and 0.48% linalool were 31.9%, 72.4%, and 74.7%, 




concentration (CC50), which were 0.02% citral, 0.04% citral, and 0.12% linalool, 
were used in further experiments.     
   
Role of Citral and Linalool in Adhesion to and Invasion into MAC-T cells by S. 
aureus 
Citral and linalool’s effect on S. aureus association to MAC-T cells are shown 
in Figure 11.  All concentrations of citral and linalool tested reduced S. aureus 
adherence to MAC-T cells compared to the control.  A concentration 0.02% citral had 
the lowest reduction at 4.5 x 103 CFU mL-1.  A concentration of 0.12% linalool 
reduced adhered S. aureus by 6.0 x 103 CFU mL-1, which was not significant from 
0.02% citral.  A concentration 0.04% citral produced the lowest reduction at 7.2 x 103 
CFU mL-1, which was not significant from 0.12% linalool.   
 Citral and linalool’s ability to inhibit S. aureus invasion of MAC-T cells is 
shown in Figure 12.  Concentrations of 0.02% and 0.04% citral were able to reduce 
invaded S. aureus by 5.2 x 103 CFU mL-1 and 9.7 x 103 CFU mL-1, respectively.  
There was a statistical difference between 0.02% citral and 0.04% citral.  The lowest 
reduction made was by 0.12% linalool, which was 1.0 x 104 CFU mL-1.  This was not 
significant different from 0.04% citral.  
 
Effects of Citral and Linalool on Expression of MAC-T Cytokine Genes and S. 
aureus Genes Involved in Virulence and Biofilms 
Figure 13 illustrates the effects of citral and linalool on MAC-T cytokine 




untreated control.  All three treatments were capable of significantly upregulating IL-
17A.  A 1 h treatment of 0.12% linalool also significantly upregulated IFNγ.  In 
addition, a 1 h treatment of 0.04% citral significantly downregulated IL-1β. 
Figure 14 shows the impact of citral and linalool on S. aureus virulence gene 
expression.  All concentrations, 0.02% citral, 0.04% citral, and 0.12% linalool, 
decreased the expression of sirA, hla, spa, and sarS.  Both concentrations of citral 
also decreased expression of agrA, sodA, hlb, and sarR.  In addition, a concentration 
of 0.04% citral reduced expression of sbi, sarA, and sigB.    
Figure 15 illustrates citral and linalool’s impact on biofilm gene expression.  
While citral had no impact on any of the biofilm genes examined, 0.12% linalool 
decreased expression of icaA, icaB, fnbB, clfA, clfB, and ebps by greater than 2 fold.  
The expression of icaC, icaD, and fnbA were not impacted by citral and linalool. 
 
Discussion 
The major components of terpeneless, cold-pressed Valencia orange oil, 
linalool, citral decanal, and valencene, were examined for their inhibitory effects on 
S. aureus growth, and alteration ability in S. aureus-MAC-T cell interaction.  Of the 
four components, only citral and linalool were capable of inhibiting S. aureus growth, 
having MIC values of 0.02% and 0.12%, respectively.  Another study has examined 
the MIC of these components on S. aureus as well, having previously determined to 
be 0.06% for citral and 0.125% for linalool (Fisher et al., 2006).  These results are 
similar to our own findings.  In addition, both citral and linalool were able to decrease 




eliminate S. aureus below detectable limits at twice that value.  Citral and linalool, in 
addition to many other terpenes, have been researched for their antimicrobial 
properties.  Their mode of action is theorized to be due to damage to the cell 
membrane of bacteria, which leads to K+ ion leakage and reduced membrane 
potential (Inoue et al., 2004).        
Citral and linalool’s effects on pre-formed biofilms were also examined.  
Linalool appeared to be stronger than citral at inhibiting biofilms.  At linalool’s MIC 
value 0.12%, it reduced pre-formed biofilms beyond that of the MIC value of citral, 
0.02%.  It should be noted that all concentrations tested resulted in statistically 
significant reductions of pre-formed biofilms compared to control.  We were able to 
find no other studies that examined citral and linalool’s impact on pre-formed 
biofilms.  Yet, we can infer some information based on studies that examined other 
terpenes’ ability to disrupt biofilms.  Other terpenes have been found to possess anti-
biofilm agents against S. aureus biofilms (Kuźma et al., 2007), meaning our results 
are consistent with past research.  As for the mode of action, one study found that 
terpenes disrupted biofilms by promoting cell separation, caused by terpenes reducing 
the fatty acid composition of the cell membrane and increasing hydrophobicity (de 
Carvalho et al., 2007).  It is possible that citral and linalool act in a similar manner, 
but further study is required.   
Cytotoxicity was tested on MAC-T cells for both citral and linalool.  All 
concentrations tested for both citral and linalool were found to be cytotoxic.  There 
were only three concentrations found to be below CC50, 0.02% citral, 0.04% citral, 




remainder of the study.  In one past study, citral was determined to have a high 
cytotoxicity in human skin cells (Hayes et al., 2002).  Yet, it should be noted that in 
vivo toxicity in rat models was found to be 100 fold lower than in vitro results (Hayes 
et al., 2002).  In addition, it was only at concentrations above 1% that citral caused 
any skin sensitization (Hayes et al., 2002).  Therefore, concentrations of 0.02% and 
0.04% citral are probably safe for in vivo use.  Linalool has also been tested for 
cytotoxicity in a past study, but again on human skins cells (Prasher et al., 2004).  
Previous results are consistent with our own, in which a large increase in cytotoxicity 
occurs between 0.125% and 0.25% (Prasher et al., 2004).  We found a large increase 
in relative cytotoxicity between 0.12% linalool, which had a relative cytotoxicity of 
31.9%, and 0.24% linalool, which had a relative cytotoxicity of 72.4%.  
Concentrations of 0.12% linalool and lower should be safe for use, but it is not 
advised to use higher concentrations.  More studies would be needed to determine the 
safe dosages for use in vivo.     
The impact of citral and linalool on MAC-T cytokine expression was also 
examined.  Citral and linalool had no impact on the expression of IL-6, IL-8, IL-12, 
and TNFα during infection.  However, all three treatments upregulated IL-17A.  
During S. aureus infection of bovine mammary epithelial cells, IL-17 is upregulated, 
which in turn upregulates expression of chemokines that target both neutrophils and 
mononuclear leucocytes (Bougarn et al., 2011).  Increased expression IL-17A could 
serve to better recruit neutrophils and leucocytes to the target area in order to combat 
infection.  In addition, 0.12% linalool also upregulated IFNγ.  IFNγ is often 




elicit the most effective immune response against the pathogen (Lee et al., 2005).  It 
is thought that S. aureus may cause the suppression of IFNγ (Lee et al., 2005).  By 
upregulating IFNγ, bovine mammary epithelial cells may be able to more effectively 
clear S. aureus infection.  Lastly, 0.04% citral downregulated IL-1β.  IL-1β is a pro-
inflammatory cytokine that is often upregulated during S. aureus infection of the 
bovine mammary gland (Simojoki et al., 2011).  Downregulation of this cytokine 
could create difficulties in clearing the infection.                  
The study then determined whether citral and linalool impacted S. aureus’ 
association to and invasion of MAC-T cells.  All of the concentrations below CC50 
were capable of decreasing association and invasion.  The most effective 
concentrations were 0.04% citral and 0.12% linalool with there being no statistically 
significant difference between the two.  While the mechanism is unclear, our results 
on gene expression of virulence genes may offer some insight into the effects of citral 
and linalool.   Both citral and linalool downregulated expression of sirA, hla, spa, and 
sarS.  However, citral alone reduced expression of agrA, sodA, hlb, and sarR.  In 
addition, only a concentration of 0.04% citral resulted in decreased expression of sbi, 
sarA, and sigB.  AgrA is transcriptional regulator for virulence gene expression and is 
considered the sole quorum-sensing regulator (Lowy, 1998; Queck et al., 2008).  It is 
possible that the downregulation of agrA could contribute to the downregulation of 
the other genes examined.  The sar protein family, sarA, sarR, and sarS, are 
regulatory proteins for cell wall and extracellular proteins (Ster et al., 2005).  Both 
sarA and sarS work antagonistically while sarR modulates the two (Ster et al., 2005).  




proteins.  SigB gene acts as another regulatory factor that impacts virulence as well as 
stress responses (Ster et al., 2005).   Its downregulation may serve to increase 
susceptibility to stressful environmental conditions. SirA is involved iron acquisition 
for S. aureus (Heinrichs et al., 1999).  As iron is a critical nutrient for infection and is 
often sequestered in cells, methods of iron acquisition are critical (Trivier et al., 
1996).  Due to the down-regulatory effects of citral and linalool on sirA, S. aureus 
may have problems obtaining iron for infection.  Sbi is an immunoglobulin-binding 
protein (Burman et al., 2008).  It plays a role in the evasion of adaptive immunity by 
binding to IgG as well as the evasion of innate immunity by binding complement 
(Burman et al., 2008).  SpA, surface protein A, also binds IgG as well (Burman et al., 
2008).  While this would not affect the in vitro work done, it may serve to limit 
infections in vivo.  Hla and hlb are both haemolysins (Ster et al., 2005).  With lowered 
expression, cell damage may be reduced.  This downregulation of major virulence 
genes may serve to inhibit S. aureus pathogenesis and infection.  However, for 
biofilm genes, only linalool appeared to be able to downregulate expression.  A 
concentration 0.12% linalool was capable of reducing expression of icaA, icaB, fnbB, 
clfA, clfB, and ebps.  IcaA and icaB are part of a larger ica operon, which also 
includes icaC and icaD.  The ica operon (icaABCD) facilitates cell to cell adhesion in 
biofilm formation (O’Gara, 2007).  This is accomplished by the production of 
polysaccharide intercellular adhesin, which is translocated to the cell surface and 
deacetylated for attachment (O’Gara, 2007).  The role of icaA in conjunction with 
icaD is to produce polysaccharide intercellular adhesion while the role of icaB is to 




these two genes may interfere with cell to cell attachment and the growth of biofilms.  
FnbA and fnbB can also initiate biofilm development (Houston et al., 2010).  
However, they appear to play larger roles in the persistence of biofilms (Atshan et al., 
2013; Houston et al., 2010).  They also help facilitate adherence to surfaces as does 
clfA and clfB (Götz, 2002) and ebps (Downer et al., 2001).  Downregulation of fnbA 
and fnbB would interfere with another mode of biofilm development as well as initial 
attachments.  Adherence would be further reduced by the reduction of clfA, clfB, and 
ebps expression.  Reduction of expression of these genes would all interfere with 
biofilm production and maintenance, which could serve to limit S. aureus 
colonization and infection.      
Citral and linalool should be considered for further research in the treatment 
of S. aureus associated mastitis.  Any issues with cytotoxicity should not present any 
problems in vivo according to past research in mice models.  Concentrations with 
relative cytotoxicity below the CC50 may have greater benefits than risks.  Both citral 
and linalool reduced in vitro growth and pre-formed biofilms.  For linalool 
treatments, this decrease in pre-formed biofilms may be due in part to downregulation 
of genes that play a role in biofilm formation and development.  Both citral and 
linalool also decreased S. aureus association and invasion, which may be due to their 
downregulation of virulence genes.  Future directions include examining the impact 




Chapter 4: Conclusion 
The first study examined the potential of terpeneless, CPV orange oil as an 
alternative to antibiotics in the treatment of S. aureus associated bovine mastitis.  In 
certain aspects, the compound was highly effective, such as reducing S. aureus 
growth and invasion of bovine epithelial mammary cells as well as increasing bovine 
epithelial mammary cell proliferation.  However, it was only capable of reducing pre-
formed biofilms at a single concentration tested, which was a modest reduction.  For 
an effective treatment, reduction of pre-formed biofilms is necessary as most cases of 
mastitis are chronic, in which biofilm formation plays a role in persistence.  In 
addition, the concentrations necessary to reduce association to epithelial mammary 
cells was very high and not the same concentration necessary to reduce pre-formed 
biofilms.  This mismatch in dosages made it a poor choice in treatment.  The second 
study examined individual components of terpeneless, CPV orange oil.  While citral, 
linalool, decanal, and valencene were initially examined, only citral and linalool were 
found to be effective at inhibiting S. aureus growth.  In addition, citral and linalool 
appeared to be more potent inhibitors of pre-formed biofilms, being effective at all 
concentrations tested.  However, only linalool was capable of reducing expression of 
major biofilm genes.  Both citral and linalool are partly cytotoxic and two 
concertation of citral (0.02% and 0.04%) and only concentration of linalool (0.12%), 
tested in this study, were deemed safe enough on bovine epithelial mammary cells.  In 
addition, unpublished research suggests that citral and linalool have no effect on 
Lactobacillus, making it a safer than traditional antibiotics for beneficial microflora.  




CPV in control mastitis in dairy cattle.  These concentrations were also capable of 
reducing interactions, both association and invasion, of bovine epithelial mammary 
cells by S. aureus, showing the ability to inhibit infection.  This inhibitory effect may 
be due in part to their downregulation of various virulence genes.  These studies 
suggest that citral and linalool may be viable candidates as alternatives to antibiotics 






Chapter 5:  List of Tables 
Table 1: Primers used for cytokine gene expression in this study. 
Genes Forward Primer (5' -> 3') Reverse Primer (5' -> 3') Reference 
IL-1β AAATGAACCGAGAAGTGGTGTT TTCCATATTCCTCTTGGGGTA
GA 
(Strandberg Lutzow et 
al., 2008) 
IL-6 CTGGGTTCAATCAGGCGAT CAGCAGGTCAGTGTTTGTGG (Strandberg Lutzow et 
al., 2008) 
IL-8 CTGTGTGAAGCTGCAGTTCT TAAGCAGACCTCGTTTCCAT (Strandberg Lutzow et 
al., 2008) 















(Aranday-Cortes et al., 
2013) 































Table 2: Primers used for S. aureus virulence gene expression in this study. 










(Garzoni et al., 2007) 
sirA GGGAAACCAAAGCGTGTTGT TGTCCATGATTCTACAGCACC
TACA 

























(Ster et al., 2005) 
SarR TCAACGCAACATTTCAAGTTAAG TCTGAGCACTTAGCAATCTCT
TTAG 











































Table 3: Primers used for S. aureus biofilm gene expression in this study. 
Genes Forward Primer (5' -> 3') Reverse Primer (5' -> 3') Reference 
icaA GAGGTAAAGCCAACGCACTC CCTGTAACCGCACCAAGTTT (Atshan et al., 2013) 
icaB ATACCGGCGACTGGGTTTAT TTGCAAATCGTGGGTATGTGT (Atshan et al., 2013) 
icaC CTTGGGTATTTGCACGCATT GCAATATCATGCCGACACCT (Atshan et al., 2013) 
icaD ACCCAACGCTAAAATCATCG GCGAAAATGCCCATAGTTTC (Atshan et al., 2013) 














(Atshan et al., 2013) 






































Table 4: Minimum Inhibitory Concentrations (MIC) of Citral, Linalool, Decanal, and 
Valencene on S. aureus 
 Citrala Linalool Decanal Valencene 
MIC Values 0.02% 0.12% >2.5% >2.5% 
aA 10% stock solution of citral, linalool, decanal, and valencene was used with each 






Chapter 6:  List of Figures 
 
Figure 1: Growth Inhibition Assay of Cold-Pressed, Terpeneless Valencia Orange 
Oil on S. aureus 
 
Growth inhibition of S. aureus during a 4 h treatment with 0.00%, 0.05%, 0.025%, 
0.0125%, and 0.00625% CPV.  Log CFU mL-1 for both bacteria were measured after 
0, 15, 30, 45, 60, 90, 120, 180, and 240 min.  A starting concentration of 105 CFU 




Figure 2: Inhibition of Pre-Formed S. aureus Biofilms by Cold-Pressed, Terpeneless 
Valencia Orange Oil 
 
The effect of citrus derived oil on preformed S. aureus biofilms.  Absorbance at 540 
nm was measured for the CPV concentrations of 0%, 0.025%, 0.05%, and 0.1%.  
Asterisks indicate significant difference (p<0.05) from 0% control based on One Way 





Figure 3: Relative Cytotoxicity of Orange Oil on MAC-T Cells 
 
Relative Cytotoxicity of CPV on MAC-T cells measured after 1 hour of treatment 
with concentrations of CPV starting at 0.025% with half step dilutions up to 0.1%.  A 
control of only DMEM supplemented with 10% FBS and 100 μg mL-1 gentamicin 




Figure 4: Inhibition of S. aureus Association to MAC-T cells by Cold-Pressed, 
Terpeneless Valencia Orange Oil 
 
Recovered associated log CFU ml-1 of S. aureus with MAC-T cells after a 1 h 
treatment with range of CPV conditions starting at 0.2% with half step dilutions down 
to 0.025%.  The control had an equivalent volume of DMSO added to the wells.  
Associated bacteria include those invaded or attached to MAC-T cells.  Significant 
differences were found (P<0.05) in log CFU ml-1 of associated bacteria in S. aureus 
when compared among groups.  Concentrations significantly different are marked 




Figure 5: Inhibition of S. aureus Invasion of MAC-T cells by Cold-Pressed, 
Terpeneless Valencia Orange Oil 
 
Invasion of MAC-T cells by S. aureus under a range of CPV conditions starting at 
0.2% with half step dilutions down to 0.025%.  These MAC-T cells were treated with 
their respective citrus oil condition for 1 h.  A concentration of 0% CPV was used a 
control.  Invasion of MAC-T cells was measured after 1 h of treatment.  
Concentrations significantly different are marked with asterisks.  There was a 
significant CPV concentration effect (P<0.05) based on one-way ANOVA and 








Figure 6: Growth Inhibition Assay of Citral and Linalool on S. aureus over 72 h 
 
A growth inhibition assay of S. aureus after being treated with only LB broth 
(control), 0.02% citral, 0.04% citral, 0.12% linalool, or 0.24% linalool in LB broth.  
This assay was performed 72 h with bacterial enumeration occurring every 24 h.  The 
starting inocula of S. aureus was 1.9 x 106 CFU mL-1.  The data illustrates the mean at 
each time point with bars representing the standard deviation.  For each time point, 
statistical significance was determined by Tukey’s HSD test.  Statistically significant 








Figure 7: Growth Inhibition Assay of 0.04% Citral and 0.24% Linalool on S. aureus 
over 3 h 
 
A growth inhibition assay of S. aureus after being treated with only LB broth 
(control), 0.04% citral, or 0.24% linalool in LB broth.  This assay was performed 3 h 
with bacterial enumeration occurring every 1 h.  The starting inocula of S. aureus was 
1.9 x 104 CFU mL-1.  The data illustrates the mean at each time point with bars 
representing the standard deviation.  For each time point, statistical significance was 






Figure 8: Inhibition of Pre-Formed S. aureus Biofilms by Citral and Linalool 
 
Inhibition of pre-formed S. aureus biofilms by citral and linalool.  Absorbances of 
biofilms were measured after 24 h of growth and another 24 h of treatment at 540 nm.  
Biofilms were either treated with only LB broth, 0.02% citral, 0.04% citral, 0.08% 
citral, 0.12% linalool, 0.24% linalool, or 0.48% linalool in LB broth.    The data 
illustrates the mean with bars representing the standard deviation.  Statistically 









Figure 9: Relative Cytotoxicity of Citral on MAC-T cells 
 
Detection of cytotoxicity of citral at concentrations of 0.02%, 0.04%, and 0.08% on 
MAC-T cells.  Cytotoxicities were determined relative to live cells in an untreated 
control. The data illustrates the mean with bars representing the standard deviation.  





Figure 10: Relative Cytotoxicity of Linalool on MAC-T Cells 
 
Detection of cytotoxicity of linalool at concentrations of 0.12%, 0.24%, and 0.48% on 
MAC-T cells.  Cytotoxicities were determined relative to live cells in an untreated 
control. The data illustrates the mean with bars representing the standard deviation.  







Figure 11: Inhibition of S. aureus Association to MAC-T cells by Citral and Linalool 
 
Association assay of S. aureus on MAC-T cells following 1 h of infection and 1 h of 
treatment with either a control of DMEM supplemented with 10% FBS, 0.02% citral, 
0.04% citral, or 0.12% linalool in DMEM supplemented with 10% FBS.  The data 
illustrates the mean with bars representing the standard deviation.  Statistically 





Figure 12: Inhibition of S. aureus Invasion of MAC-T cells by Citral and Linalool 
 
Invasion assay of S. aureus on MAC-T cells following 1 h of infection and 1 h of 
treatment with either a control of DMEM supplemented with 10% FBS, 0.02% citral, 
0.04% citral, or 0.12% linalool in DMEM supplemented with 10% FBS.  The data 
illustrates the mean with bars representing the standard deviation.  Statistically 













Figure 13: Relative Expression of MAC-T Cytokine Genes after Infection and 
Treatment 
 
Gene expression of MAC-T cytokine genes after 1 h of infection with S. aureus and 1 
h of treatment with either a control of DMEM supplemented with 10% FBS, 0.02% 
citral, 0.04% citral, or 0.12% linalool in DMEM supplemented with 10% FBS.  











Figure 14: Relative Expression of S. aureus Virulence Genes During Infection of 
MAC-T Cells After Being Treated with Citral and Linalool 
 
Gene expression of S. aureus virulence genes after 1 h of infection of MAC-T cells 
and 1 h of treatment with either a control of DMEM supplemented with 10% FBS, 
0.02% citral, 0.04% citral, or 0.12% linalool in DMEM supplemented with 10% FBS.  








Figure 15: Relative Expression of S. aureus Biofilm Genes After Being Treated with 
Citral and Linalool for 24 h 
 
Gene expression of S. aureus biofilm genes after 24 h of growth and 24 h of treatment 
with either a control of LB broth, 0.02% citral, 0.04% citral, or 0.12% linalool in LB 
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